Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

"China conditionally approves Hutchmed’s Tazverik for follicular lymphoma" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this ...